Mark N Gaze

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi request reprint Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma
    M N Gaze
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
    Q J Nucl Med Mol Imaging 57:66-78. 2013
  2. doi request reprint Results of a quality assurance review of external beam radiation therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-risk Neuroblastoma Trial: a SIOPEN study
    Mark N Gaze
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    Int J Radiat Oncol Biol Phys 85:170-4. 2013
  3. doi request reprint Development of an electronic database for quality assurance of radiotherapy in the International Society of Paediatric Oncology (Europe) high risk neuroblastoma study
    Mark N Gaze
    Department of Oncology, University College London Hospital, UK
    Radiother Oncol 97:593-5. 2010
  4. doi request reprint 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma
    Jennifer E Gains
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    J Nucl Med 52:1041-7. 2011
  5. doi request reprint Intensity-modulated arc therapy to improve radiation dose delivery in the treatment of abdominal neuroblastoma
    Jennifer E Gains
    Department of Oncology, University College London Hospitals NHS Foundation Trust, First Floor Central, 250 Euston Road, London NW1 2PG, UK
    Future Oncol 9:439-49. 2013
  6. doi request reprint 18F-fluoroethylcholine (18F-Cho) PET/MRI functional parameters in pediatric astrocytic brain tumors
    Francesco Fraioli
    From the Department of Nuclear Medicine, and Department of Paediatric and Adolescent Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom Department of Paediatric Oncology, Great Ormond Street Hospital, London, UK Department of Radiology University, and Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    Clin Nucl Med 40:e40-5. 2015
  7. doi request reprint Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma
    Michael A Kosmin
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
    Eur J Nucl Med Mol Imaging 39:597-601. 2012
  8. doi request reprint Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy
    Valerie Said-Conti
    Department of Paediatric Nephrology, Great Ormond Street Hospital NHS Trust, London, UK
    Pediatr Nephrol 28:2053-6. 2013
  9. doi request reprint 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis
    Nikolaos D Papathanasiou
    Institute of Nuclear Medicine, University College London Hospital, London, United Kingdom
    J Nucl Med 52:519-25. 2011

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma
    M N Gaze
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
    Q J Nucl Med Mol Imaging 57:66-78. 2013
    ..Only in this way will it be possible for [131I]-mIBG to be used to its best advantage in the complex multimodality treatment schedules required for high-risk neuroblastoma...
  2. doi request reprint Results of a quality assurance review of external beam radiation therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-risk Neuroblastoma Trial: a SIOPEN study
    Mark N Gaze
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    Int J Radiat Oncol Biol Phys 85:170-4. 2013
    ..This study reviewed the compliance of plans with the radiation therapy guidelines of the International Society of Paediatric Oncology (Europe) Neuroblastoma Group (SIOPEN) High-Risk Trial protocol...
  3. doi request reprint Development of an electronic database for quality assurance of radiotherapy in the International Society of Paediatric Oncology (Europe) high risk neuroblastoma study
    Mark N Gaze
    Department of Oncology, University College London Hospital, UK
    Radiother Oncol 97:593-5. 2010
    ..This will enable investigation of the relationship between radiotherapy quality and local control...
  4. doi request reprint 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma
    Jennifer E Gains
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    J Nucl Med 52:1041-7. 2011
    ....
  5. doi request reprint Intensity-modulated arc therapy to improve radiation dose delivery in the treatment of abdominal neuroblastoma
    Jennifer E Gains
    Department of Oncology, University College London Hospitals NHS Foundation Trust, First Floor Central, 250 Euston Road, London NW1 2PG, UK
    Future Oncol 9:439-49. 2013
    ..001). IMAT would have enabled delivery of the full protocol dose in eight out of ten protocol-noncompliant patients. IMAT may improve outcomes through improved protocol compliance and better dose distributions...
  6. doi request reprint 18F-fluoroethylcholine (18F-Cho) PET/MRI functional parameters in pediatric astrocytic brain tumors
    Francesco Fraioli
    From the Department of Nuclear Medicine, and Department of Paediatric and Adolescent Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom Department of Paediatric Oncology, Great Ormond Street Hospital, London, UK Department of Radiology University, and Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
    Clin Nucl Med 40:e40-5. 2015
    ....
  7. doi request reprint Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma
    Michael A Kosmin
    Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
    Eur J Nucl Med Mol Imaging 39:597-601. 2012
    ..In this study we audited BP changes in patients receiving (131)I-mIBG therapy for neuroblastoma to identify BP-related adverse events (AE) and possible predictive factors...
  8. doi request reprint Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy
    Valerie Said-Conti
    Department of Paediatric Nephrology, Great Ormond Street Hospital NHS Trust, London, UK
    Pediatr Nephrol 28:2053-6. 2013
    ..The modalities of treatment include reduction in immunosuppression, cranial radiotherapy (CRT), intravenous and intrathecal rituximab when CD20 is expressed on B-lymphocytes and PTLD cells, and chemotherapy...
  9. doi request reprint 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis
    Nikolaos D Papathanasiou
    Institute of Nuclear Medicine, University College London Hospital, London, United Kingdom
    J Nucl Med 52:519-25. 2011
    ..The aim of our study was to evaluate prospectively the diagnostic performance and prognostic significance of (18)F-FDG PET/CT in comparison with (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging in patients with high-risk neuroblastoma...